Mar 01

Clinical Trials Arena: Artiva Prepares to Kick off Phase I/II Trial for NK Cell Therapy

Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).

CEO Fred Aslan told the Clinical Trials Arena that the company is currently enrolling patients on the trial with hopes to dose the first patient within H1 2024.

Read the full article here.

Recent Posts

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

To Artiva’s knowledge, this marks the first patient to receive an allogeneic, off-the-shelf NK cell therapy in a U.S. clinical trial for treatment of an autoimmune disease Data demonstrated AlloNK drove deep depletion of peripheral B-cells and complete responses in relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL) patients in ongoing clinical trial, supporting potential mechanism of...

BiotechTV: Using NK Cell Therapies for Autoimmune Disease and Cancer with Artiva’s CEO

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the interview here.

Clinical Trials Arena: Artiva Prepares to Kick off Phase I/II Trial for NK Cell Therapy

Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). CEO Fred Aslan told the Clinical Trials Arena that the company is currently enrolling patients on the trial with hopes to dose the first patient within H1 2024. Read the full article here.